Author: Walker Newell

null

Securities litigation risk is generally highest for companies in the first three years following an initial public offering (IPO). This has something to do with the growing pains that sometimes accompany a company's early years in the public markets. But it has more to do with the New Deal Congress's legislative drafting decisions from 93 years ago.

Section 11 of the Securities Act of 1933 (the "Securities Act") prohibits fraud in connection with securities offerings. While Section 11 can be used to sue companies for secondary stock offerings, it's more commonly used to sue companies for supposed fraud related to disclosures in IPO S-1 registration statements.

Section 11 is a strict liability provision (with no intent requirement). As a result, IPO cases are particularly attractive to plaintiffs' lawyers and can be tough sledding for companies and defense lawyers. Because of these and other factors, a high percentage of young public companies face private securities litigation in the years immediately post-IPO, and many of these cases end in costly settlements.

When securities plaintiffs sue a company, they routinely include the company's senior officers (most commonly, the CEO and CFO) as individual defendants. This pleading strategy maps to the federal securities laws, which make senior officers responsible for certifying the accuracy of Securities and Exchange Commission (SEC) filings. For plaintiffs, it has the added benefit of exerting more settlement pressure on the company.

In IPO cases, plaintiffs have yet another tool in their toolbox. In IPOs, investment bank underwriters buy shares from the company and sell those shares to the market. Thanks, again, to the New Deal Congress and the Securities Act, bank underwriters may be held liable to the share buyers for allegedly false statements in the registration statement. And, indeed, securities plaintiffs routinely also name underwriters as defendants in IPO litigation against public companies.

In the D&O context, the term "underwriter" typically refers to underwriters at the insurance companies who issue D&O policies. Throughout this article, however, "underwriter" refers not to insurance underwriters but instead to investment banks that underwrite IPOs.

Underwriter indemnification and D&O policy endorsements

Bank underwriters generally require companies to indemnify them for defense costs and settlements related to allegedly false statements made in IPO registration statements. This indemnification obligation often results in an even heavier cost burden for companies facing IPO litigation. High costs and the leverage of having numerous defendants at the table can help shareholder plaintiffs as companies are often incentivized to settle when cases proceed beyond the motion-to-dismiss stage, even if the allegations are relatively weak.

After the hard D&O insurance market of the early 2020s, insurer competition has often yielded better pricing and more expansive coverage options for new public companies. Among other coverage enhancements that may be available in today's market, D&O policies for newly public companies may be endorsed to include coverage for the costs of indemnifying underwriters.

This coverage tends to be keyed to the company's indemnification obligations under the underwriting agreement, which typically extend to claims relating to supposed untrue statements made in the registration statement. Claims brought by a company against a bank underwriter may be excluded.

Here are some key considerations that IPO companies should keep in mind when considering an underwriter endorsement:

Limits erosion

Bank underwriter endorsements are typically offered as a shared limit with the primary policy (excess insurers may or may not follow). To illustrate how this works, assume a company has a $5 million primary D&O policy with a shared limit underwriter endorsement. The company, its directors and officers, and its underwriters are all sued in IPO litigation, and a shareholder derivative suit follows. The company begins incurring the following costs:

  • Directly defending itself in the litigation
  • Indemnifying the defense costs of directors and officers
  • Indemnifying the defense costs of underwriters

Each of those expenses would generally draw from the same primary layer of insurance. In contrast, if there is no underwriter endorsement, the company would likely pay underwriter indemnification directly from the treasury, leaving more limits available for the individual directors and officers.

Limits analysis and adequacy

Data-driven, multi-faceted D&O limits analysis is important for all public companies. For IPO companies considering underwriter coverage, this is especially true. Companies exploring underwriter coverage should consider the impact this shared limit would have on the coverage otherwise available to individual directors and officers. Under such circumstances, they may consider purchasing additional Side A DIC limits to ensure they have adequate limits to attract and retain qualified senior leaders.

As a reminder, Side A DIC is a separate policy that sits excess of the ABC D&O tower. Unlike the ABC policies, Side A DIC coverage solely benefits individual directors and officers and isn't shared with the company.

Additional premium

IPO underwriter endorsements typically aren't free. In light of the potential for rapid limit erosion, insurers usually require additional premium to extend this coverage. D&O pricing for IPOs has come down significantly from its hard market peak, but it's nevertheless a significant (and recurring) expense at a time when the company is trying to prove itself for the first time to the public markets. While additional premiums for underwriter coverage shouldn't be significant relative to total D&O spend, companies seeking lower costs may elect to instead self-insure this risk. The trade-off, of course, is between higher up-front costs and higher potential balance sheet exposure on the back end.

Getting D&O coverage right from the start

A well-constructed IPO D&O program can be a key component of a company's risk mitigation and controls strategy as it prepares for a long life on the public markets. The IPO program establishes the foundation for a company's public company D&O tower, and it's important to get it right the first time. Nuanced coverage decisions — like underwriter endorsements — involve trade-offs and should be considered carefully in dialogue with insurance advisors who are highly experienced in placing IPO D&O programs.

Published November 2026

Author Information


Disclaimer

The information contained herein is offered as insurance Industry guidance and provided as an overview of current market risks and available coverages and is intended for discussion purposes only. This publication is not intended to offer financial, tax, legal or client-specific insurance or risk management advice. General insurance descriptions contained herein don't include complete Insurance policy definitions, terms, and/or conditions, and should not be relied on for coverage interpretation. Actual insurance policies must always be consulted for full coverage details and analysis. Gallagher publications may contain links to non-Gallagher websites that are created and controlled by other organizations. We claim no responsibility for the content of any linked website, or any link contained therein. The inclusion of any link doesn't imply endorsement by Gallagher, as we have no responsibility for information referenced in material owned and controlled by other parties. Gallagher strongly encourages you to review any separate terms of use and privacy policies governing use of these third-party websites and resources. Insurance brokerage and related services provided by Arthur J. Gallagher Risk Management Services, LLC License Nos. IL 100292093 / CA 0D69293 and its US licensed retail brokerage affiliates © 2026 Arthur J. Gallagher & Co., and affiliates & subsidiaries.